Evidence digest
What the research on Cagrilintide actually shows
The indexed literature on Cagrilintide includes human clinical or observational records (4 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether Cagrilintide is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
Updated 25 Aug 2026 · 4 studies indexed · 4 human · compound record
- Studies indexed
- 4
- Human evidence
- 4
- Preclinical only
- 0
What is and is not established
What the literature supports
- Human clinical or observational records are indexed for Cagrilintide (4).
- Published research is indexed back to 2021, with roughly 93 PubMed records located.
- It is listed by one or more vendors tracked in this index.
What is NOT established
- This index does not evaluate whether Cagrilintide is safe or effective for any use.
- Material sold by the vendors indexed here is labeled for laboratory research use only and is not a regulator-approved medicine in that form.
- No dosing, protocol or human-use guidance is provided or implied anywhere in this index.
Studies indexed
1 meta-analysis · 3 human — controlled trial
| Study | Evidence type | Model | n | What it reported | Source |
|---|---|---|---|---|---|
| Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysisBMJ (Clinical research ed.) · 2024 | Meta-analysis | Not recorded | — | To evaluate the comparative efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on glycaemic control, body weight, and lipid profile in adults with type 2 diabetes. Systematic review and network meta-analysis. PubMed, Web of Science, Cochrane Central Register of Controlled Trials (CENTRAL), and Embase from database inception to 19 August 2023. Eligible randomised controlled trials enrolled adults with type 2 diabetes who received GLP-1RA treatments and… | PMID 38286487 |
| Coadministered Cagrilintide and Semaglutide in Adults with Overweight or ObesityThe New England journal of medicine · 2025 | Human — controlled trial | Not recorded | — | Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg has shown promising results in early-phase trials; the efficacy of the combination (known as CagriSema) on weight loss in persons with either overweight and coexisting conditions or obesity is unknown. In a phase 3a, 68-week, multicenter, double-blind, placebo-controlled and active-controlled trial, we enrolled adults without diabetes who had a body-ma… | PMID 40544433 |
| Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 DiabetesThe New England journal of medicine · 2025 | Human — controlled trial | Not recorded | — | Cagrilintide and semaglutide have each been shown to induce weight loss as monotherapies. Data are needed on the coadministration of cagrilintide and semaglutide (called CagriSema) for weight management in adults with type 2 diabetes, including those in a subgroup who are undergoing continuous glucose monitoring. In this phase 3a, double-blind, randomized, placebo-controlled trial conducted in 12 countries, we assigned adults with a body-mass index of 27 or more, a glycated h… | PMID 40544432 |
| Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trialLancet (London, England) · 2021 | Human — controlled trial | Not recorded | — | Natural amylin is a pancreatic hormone that induces satiety. Cagrilintide is a long-acting amylin analogue under investigation for weight management. We assessed the dose-response relationship of cagrilintide regarding the effects on bodyweight, safety, and tolerability. We conducted a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial at 57 sites including hospitals, specialist clinics, and primary care centres in ten … | PMID 34798060 |
Vendors listing Cagrilintide
The evidence above describes the published literature. What any individual vial contains is a separate question, answered by that vendor’s certificate records rather than by any study on this page.
| Vendor | Score · Coverage | Certificates | |
|---|---|---|---|
| Polaris Peptides | 93.877% | 2 | profile → |
| Next Gen Peptides | 93.897% | 3 | profile → |
| PeptidePlugs | 89.790% | 2 | profile → |
| Hydro Research Peptides | 88.289% | 1 | profile → |
| American Peptides | 83.6100% | 0 | profile → |
| Northline Labs | 79.493% | 0 | profile → |
| NeuroLabs Research | 79.386% | 1 | profile → |
| Good Science Bio | 79.275% | 0 | profile → |
| Ascension Peptides | 78.186% | 1 | profile → |
| Licensed Peptides | 7789% | 0 | profile → |
| Simple Peptide | 7489% | 1 | profile → |
| Vertex Labs | 70.170% | 1 | profile → |
| Disguised Alpha | 69.150% | 0 | profile → |
| BioLongevity Labs | 67.274% | 0 | profile → |
| Mile High Compounds | 65.494% | 1 | profile → |
How to read this page
This digest describes what published research exists and what it does not establish. It is not a recommendation, contains no dosing information or protocols, and makes no claim that any compound is safe or effective for any purpose. Material listed by indexed vendors is labeled for laboratory research use only.